on INTEGRAGEN (EPA:ALINT)
IntegraGen: Annual Review and Continued Strategic Refocusing
IntegraGen's 2025 revenue is projected at €5.021 million, down from €8.489 million in 2024. This decrease reflects a challenging environment for the biotechnology sector, marked by budget constraints in research. IntegraGen is now focusing on biopharmaceutical clinical trials, strengthening its position through renewed certifications.
Available cash reached €1.115 million as of December 31, 2025. With a loan repaid to OncoDNA, the company anticipates financial visibility until the third quarter of 2026. IntegraGen aims to improve its profitability and expand its customer base in 2026, with clinical projects in development.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INTEGRAGEN news